Hemminki A - Search Results

1

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.

Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, Laasonen L, Partanen K, Joensuu T, Zhao F, Kanerva A, Hemminki A. Liikanen I, et al. Among authors: hemminki o, hemminki a. Mol Ther. 2013 Jun;21(6):1212-23. doi: 10.1038/mt.2013.51. Epub 2013 Apr 2. Mol Ther. 2013. PMID: 23546299 Free PMC article.

2

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression.

Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel DT, Alvarez RD. Hemminki A, et al. Mol Ther. 2001 Sep;4(3):223-31. doi: 10.1006/mthe.2001.0446. Mol Ther. 2001. PMID: 11545613 Free article.

3

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Kanerva A, et al. Among authors: hemminki a. Clin Cancer Res. 2002 Jan;8(1):275-80. Clin Cancer Res. 2002. PMID: 11801569

4

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1266-70. Cancer Res. 2002. PMID: 11888888

5

The flt-1 promoter for transcriptional targeting of teratocarcinoma.

Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1271-4. Cancer Res. 2002. PMID: 11888889

6

Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.

Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT. Arafat WO, et al. Among authors: hemminki a. Gene Ther. 2002 Feb;9(4):256-62. doi: 10.1038/sj.gt.3301639. Gene Ther. 2002. PMID: 11896464

7

Adenoviruses in oncology: a viable option?

Hemminki A, Alvarez RD. Hemminki A, et al. BioDrugs. 2002;16(2):77-87. doi: 10.2165/00063030-200216020-00001. BioDrugs. 2002. PMID: 11985481 Review.

8

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Among authors: hemminki a. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 Free article.

9

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT. Haviv YS, et al. Among authors: hemminki a. Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029

10

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.

Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Hemminki A, et al. Hum Gene Ther. 2002 Aug 10;13(12):1505-14. doi: 10.1089/10430340260185139. Hum Gene Ther. 2002. PMID: 12215271 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

341 results

Search Page